Paul Baas

6PUBLICATIONS
51CO-AUTHORS
Memory and attentionPredictive and prognostic markersMedical infection agents (incl. prions)Radiation therapyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 10, 2026
Reply to: "Beyond Response Rates: Interpreting Long-Term Benefit in CheckMate 743" and "Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743".

|Feb 24, 2026
Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.

Arnaud Scherpereel, Paul Baas, Anna K Nowak

|Aug 07, 2025
Pleural mesothelioma.

Dean A Fennell, Yoshitaka Sekido, Paul Baas

|Jul 22, 2025
Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer.

Justin Huang, Willemijn S M E Theelen, Zineb Belcaid

|Feb 12, 2025
Prevalence and Clinical Association of CD276 (B7-H3) Expression in Pleural Mesothelioma: Results From the European Thoracic Platform Mesoscape Project.

Martina Haberecker, Jan H Rüschoff, Charitini Andriakopoulou

|Apr 30, 2024
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial.

Martin Schuler, Kristof Cuppens, Till Plönes

Pageof 1

Frequent Collaborators

3 joint publications

Solange Peters

2 joint publications

Anne S Tsao

2 joint publications

Adam Lee

2 joint publications

Francesco Grossi